Avadel Pharmaceuticals PLC
AVDL18.830USD
+0.130+0.70%
Cierre 11/11, 16:00（ET）Cotizaciones retrasadas 15 min
1.83BCap. mercado
PérdidaP/E TTM
Más Datos de Avadel Pharmaceuticals PLC Compañía
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Información de Avadel Pharmaceuticals PLC
Símbolo de cotizaciónAVDL
Nombre de la empresaAvadel Pharmaceuticals PLC
Fecha de salida a bolsaJan 16, 1952
Director ejecutivoMr. Gregory J. (Greg) Divis, Jr.
Número de empleados188
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 16
DirecciónBlock 10-1 Blanchardstown Corporate Park
CiudadDUBLIN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísIreland
Código postal15
Teléfono35319015201
Sitio Webhttps://www.avadel.com/
Símbolo de cotizaciónAVDL
Fecha de salida a bolsaJan 16, 1952
Director ejecutivoMr. Gregory J. (Greg) Divis, Jr.
Ejecutivos de Avadel Pharmaceuticals PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
+5.27%
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
+10.57%
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
89.03K
+14.10%
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
87.80K
-12.55%
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
+16.20%
Ms. Susan Rodriguez
Ms. Susan Rodriguez
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jerad Seurer
Mr. Jerad Seurer
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
Mr. Gregory J. (Greg) Divis, Jr.
Mr. Gregory J. (Greg) Divis, Jr.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Naseem Amin, M.D.
Dr. Naseem Amin, M.D.
Independent Director
Independent Director
--
--
Ms. Courtney Turiano
Ms. Courtney Turiano
Investor Relations
Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
+5.27%
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
+10.57%
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
89.03K
+14.10%
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
87.80K
-12.55%
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
+16.20%
Ms. Susan Rodriguez
Ms. Susan Rodriguez
Chief Operating Officer
Chief Operating Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 3 de mar
Divisa: USDActualizado: lun., 3 de mar
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
22.33M
100.00%
Ireland
0.00
0.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
Estadísticas de accionistas
Actualizado: mar., 11 de nov
Actualizado: mar., 11 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Janus Henderson Investors
11.40%
Brandes Investment Partners, L.P.
6.64%
Two Seas Capital LP
6.30%
BlackRock Institutional Trust Company, N.A.
6.12%
The Vanguard Group, Inc.
5.66%
Otro
63.88%
Accionistas
Accionistas
Proporción
Janus Henderson Investors
11.40%
Brandes Investment Partners, L.P.
6.64%
Two Seas Capital LP
6.30%
BlackRock Institutional Trust Company, N.A.
6.12%
The Vanguard Group, Inc.
5.66%
Otro
63.88%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
31.44%
Investment Advisor/Hedge Fund
29.01%
Hedge Fund
24.24%
Individual Investor
4.79%
Venture Capital
3.44%
Research Firm
1.32%
Pension Fund
0.51%
Bank and Trust
0.36%
Insurance Company
0.03%
Otro
4.85%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
382
84.18M
86.25%
-22.86M
2025Q2
375
87.44M
90.23%
-20.44M
2025Q1
377
85.31M
88.05%
-24.78M
2024Q4
354
86.56M
89.59%
-16.46M
2024Q3
334
81.87M
84.98%
-15.41M
2024Q2
299
81.11M
84.30%
-2.77M
2024Q1
258
76.98M
80.25%
+5.42M
2023Q4
226
62.92M
70.15%
-3.93M
2023Q3
220
60.11M
69.62%
-5.86M
2023Q2
213
57.67M
66.98%
-1.24M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
11.13M
11.46%
-2.46M
-18.10%
Jun 30, 2025
Brandes Investment Partners, L.P.
6.49M
6.68%
+820.47K
+14.48%
Jun 30, 2025
Two Seas Capital LP
6.16M
6.34%
+1.21M
+24.43%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.98M
6.16%
+1.29M
+27.56%
Jun 30, 2025
The Vanguard Group, Inc.
5.54M
5.71%
+1.66M
+42.73%
Jun 30, 2025
Tontine Asset Management, LLC
5.18M
5.33%
-950.54K
-15.51%
Jun 30, 2025
Polar Capital LLP
4.00M
4.12%
-356.63K
-8.19%
Jun 30, 2025
Kotler (Kevin)
3.72M
3.83%
-1.01M
-21.37%
Feb 12, 2024
Vivo Capital, LLC
2.68M
2.76%
--
--
Jun 30, 2025
Wealth Effects LLC
2.35M
2.43%
-14.30K
-0.60%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Invesco Pharmaceuticals ETF
2.75%
Innovator IBD 50 Fund ETF
2.64%
iShares Neuroscience and Healthcare ETF
2.45%
SPDR S&P Pharmaceuticals ETF
1.82%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.37%
iShares U.S. Pharmaceuticals ETF
0.55%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.36%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.19%
JPMorgan Fundamental Data Science Small Core ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.15%
Ver más
Invesco Pharmaceuticals ETF
Proporción2.75%
Innovator IBD 50 Fund ETF
Proporción2.64%
iShares Neuroscience and Healthcare ETF
Proporción2.45%
SPDR S&P Pharmaceuticals ETF
Proporción1.82%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.37%
iShares U.S. Pharmaceuticals ETF
Proporción0.55%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proporción0.36%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.19%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0.16%
Invesco Nasdaq Biotechnology ETF
Proporción0.15%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
